BioPharmSignal logoBioPharmSignal

Biotech News

TELA Bio Reports Second Quarter 2026 Financial Results

TELA Bio (TELA)TELA BioEarnings

MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026.

Related news

TELATELA Bio2026-07-20 20:05 EST

TELA Bio to Announce Second Quarter 2026 Financial Results

TELATELA Bio2026-05-12 20:05 EST

TELA Bio Reports First Quarter 2026 Financial Results

View all latest news

TELA Bio

Soft-Tissue Reconstruction Company TELA Bio develops medical devices for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery. Reinforced Tissue Matrices The OviTex portfolio combines biologic tissue with polymer reinforcement to provide strength while supporting tissue remodeling. Commercial Surgical...

Recent company news

TELATELA Bio2026-08-10 20:05 EST

TELA Bio Reports Second Quarter 2026 Financial Results

TELATELA Bio2026-08-05 20:05 EST

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELATELA Bio2026-08-04 11:00 EST

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

TELATELA Bio2026-07-29 20:05 EST

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELATELA Bio2026-07-20 20:05 EST

TELA Bio to Announce Second Quarter 2026 Financial Results

Stock data

Close
0.65 USD
Market cap
40.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States